Videos
Sensimed CEO David Bailey recounts his maiden presentation to OIS and shares information on the company’s recent financing, including a commitment from a new strategic…
Read MoreRobert Dempsey, head of the ophthalmics franchise for Shire, lays out how Shire rolled out the commercial launch of Xiidra, the company’s new potential blockbuster…
Read MoreMonty Montoya, CEO, introduces SightLife Surgical, the for-profit subsidiary of SightLife that he says will enable the group to complete its mission of eliminating treatable…
Read MoreOIS Co-Chair Emmett T. Cunningham Jr., MD, PhD, MPH laid out hopeful – and cautionary – signs facing the ophthalmology industry as he kicked off…
Read MoreFrederic Guerard, worldwide business franchise head, ophthalmology for Novartis, sits down with OIS TV to explain how the “conscious uncoupling” with Alcon will impact Novartis’…
Read MoreMany see optical coherence tomography (OCT) angiography as a promising new technology, but David Huang, MD, PhD, Peterson professor of ophthalmology at the Casey Eye…
Read MoreOIS founder and co-chair Emmett Cunningham Jr., MD, welcomes attendees to the first annual Ophthalmology Innovation Summit held prior to the annual meeting of the…
Read MoreAron Shapiro, vice president at Ora Inc., gives a comprehensive overview of the challenges and opportunities of retina therapies. Shapiro discusses Ora’s early work with…
Read MorePars plana vitrectomy is almost a half-century old, and the earliest probes were powered by batteries, said Cynthia A. Toth, MD, the Joseph A.C. Wadsworth…
Read MoreCedric Francois, CEO, Apellis Pharmaceuticals, hopes to deliver positive results to the company’s Phase II clinical trials of APL-2, a peptide targeting the C3 inhibitor…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.